| Validation of N-myristoyltransferase as an antimalarial drug target using an integrated chemical biology approach MH Wright, B Clough, MD Rackham, K Rangachari, JA Brannigan, ... Nature chemistry 6 (2), 112-121, 2014 | 241 | 2014 |
| Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2 A Mares, AH Miah, IED Smith, M Rackham, AR Thawani, J Cryan, ... Communications biology 3 (1), 140, 2020 | 178 | 2020 |
| A caged E3 ligase ligand for PROTAC-mediated protein degradation with light CS Kounde, MM Shchepinova, CN Saunders, M Muelbaier, MD Rackham, ... Chemical Communications 56 (41), 5532-5535, 2020 | 108 | 2020 |
| Discovery of Novel and Ligand-Efficient Inhibitors of Plasmodium falciparum and Plasmodium vivaxN-Myristoyltransferase MD Rackham, JA Brannigan, DK Moss, Z Yu, AJ Wilkinson, AA Holder, ... Journal of Medicinal Chemistry 56 (1), 371-375, 2013 | 83 | 2013 |
| Design and Synthesis of High Affinity Inhibitors of Plasmodium falciparum and Plasmodium vivax N-Myristoyltransferases Directed by Ligand Efficiency Dependent … MD Rackham, JA Brannigan, K Rangachari, S Meister, AJ Wilkinson, ... Journal of Medicinal Chemistry 57 (6), 2773-2788, 2014 | 82 | 2014 |
| N-Myristoyltransferase as a potential drug target in malaria and leishmaniasis EW Tate, AS Bell, MD Rackham, MH Wright Parasitology 141 (1), 37-49, 2014 | 82 | 2014 |
| Optimization of a series of RIPK2 PROTACs AH Miah, IED Smith, M Rackham, A Mares, AR Thawani, R Nagilla, ... Journal of Medicinal Chemistry 64 (17), 12978-13003, 2021 | 54 | 2021 |
| Discovery of high affinity inhibitors of Leishmania donovani N-myristoyltransferase MD Rackham, Z Yu, JA Brannigan, WP Heal, D Paape, KV Barker, ... MedChemComm 6 (10), 1761-1766, 2015 | 35 | 2015 |
| Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor agonists GA Brown, JE Cansfield, MS Congreve, MA O'brien, M Pickworth, ... US Patent 9,670,183, 2017 | 29 | 2017 |
| Muscarinic agonists GA Brown, MS Congreve, M Pickworth, MD Rackham, BG Tehan US Patent 10,548,884, 2020 | 13 | 2020 |
| Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists GA Brown, JE Cansfield, MS Congreve, MA O'brien, M Pickworth, ... US Patent 10,196,380, 2019 | 13 | 2019 |
| Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor agonists GA Brown, JE Cansfield, MS Congreve, MA O'brien, M Pickworth, ... US Patent 9,926,297, 2018 | 12 | 2018 |
| Bicyclic aza compounds as muscarnic M1 receptor and/or M4 receptor antagonists GA Brown, JE Cansfield, MS Congreve, MA O'brien, M Pickworth, ... US Patent 10,385,039, 2019 | 9 | 2019 |
| Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor GA Brown, JE Cansfield, MS Congreve, MA O'brien, M Pickworth, ... US Patent 10,689,368, 2020 | 8 | 2020 |
| Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor GA Brown, JE Cansfield, MS Congreve, MA O'brien, M Pickworth, ... US Patent 10,961,225, 2021 | 7 | 2021 |
| Compounds LN Casillas, JD Harling, AH Miah, MD Rackham, IED Smith US Patent 10,435,391, 2019 | 7 | 2019 |
| Muscarinic agonists GA Brown, MS Congreve, M Pickworth, MD Rackham, BG Tehan US Patent 11,324,738, 2022 | 6 | 2022 |
| Conjugates comprising RIPK2 inhibitors LN Casillas, JD Harling, AH Miah, MD Rackham, IED Smith US Patent 10,781,205, 2020 | 4 | 2020 |
| Novel compounds and their use in therapy R Leatherbarrow, E Tate, Z Yu, M Racklam London Patent WO 83991, 13, 2013 | 4 | 2013 |
| Bicyclic aza compounds as muscarinic m1 receptor agonists. GA Brown, JE Cansfield, MS Congreve, MA O'brien, M PICKWORTH, ... | 2 | 2015 |
